» Articles » PMID: 37144035

Role of Luteinizing Hormone Elevation in Outcomes of Ovulation Induction with Letrozole for Polycystic Ovary Syndrome

Overview
Specialty General Medicine
Date 2023 May 5
PMID 37144035
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: The effect of elevated luteinizing hormone (LH) on the clinical outcomes of ovulation induction (OI) in infertile anovulatory patients with polycystic ovary syndrome (PCOS) remains controversial. This retrospective study included PCOS patients undergoing intrauterine insemination (IUI) following letrozole (LE) stimulation without OC pretreatment.

Materials And Methods: A retrospective cohort analysis was conducted in a single, academic ART center from January 2013 to May 2019. In total, 835 IUI cycles of PCOS patients treated with letrozole were collected for the analysis. Cohorts were separated based on the level of basal LH (bLH) and LH level after letrozole administration (LH) during OI. OI response and reproductive outcomes were evaluated for each cohort.

Results: No adverse effects of dysregulated levels of either bLH or LH on ovulation rate or reproductive outcomes were observed. Furthermore, the cohort of individuals with normal bLH and high LH levels, exclusive of LH surge, exhibited significantly higher rates of clinical pregnancy (30.3% vs. 17.3%,  = 0.002) and live birth (24.2% vs. 15.2%,  = 0.024) than those with normal bLH and normal LH

Conclusion: These results indicated that high LH levels in PCOS are not solid evidence of poor prognosis of letrozole-induced ovulation, while elevated LH may be a prospective predictor for better OI outcomes. It seems that preinhibition of LH secretion is not needed.

Citing Articles

Pretreatment with oral contraceptive pills in women with PCOS scheduled for IVF: a randomized clinical trial.

Gao J, Mai Q, Zhong Y, Miao B, Chen M, Luo L Hum Reprod Open. 2024; 2024(2):hoae019.

PMID: 39697220 PMC: 11653855. DOI: 10.1093/hropen/hoae019.


Competence of Combined Low Dose of Human Chorionic Gonadotropin (HCG) and Clomiphene Citrate (CC) Versus Continued CC during Ovulation Induction in Women with CC-Resistant Polycystic Ovarian Syndrome: A Randomized Controlled Trial.

Thabet M, Abdelhafez M, Elshamy M, Albahlol I, Fayala E, Wageeh A Medicina (Kaunas). 2024; 60(8).

PMID: 39202581 PMC: 11356540. DOI: 10.3390/medicina60081300.


The comparison between fixed versus degressive doses of medroxyprogesterone acetate combined with letrozole in patients of progestin-primed ovarian stimulation protocol: a propensity score-matched study.

Zhang Y, Li H, Zhu S, Jiang S, Zhao W, Wang X Front Endocrinol (Lausanne). 2023; 14:1295787.

PMID: 38155955 PMC: 10754509. DOI: 10.3389/fendo.2023.1295787.

References
1.
Palomba S, Falbo A, Orio Jr F, Russo T, Tolino A, Zullo F . Pretreatment with oral contraceptives in infertile anovulatory patients with polycystic ovary syndrome who receive gonadotropins for controlled ovarian stimulation. Fertil Steril. 2007; 89(6):1838-42. DOI: 10.1016/j.fertnstert.2007.05.035. View

2.
Ozdemir U, Ozaksit G, Cakir Gungor A, Aydogan M . Letrozole usage adjuvant to gonadotropins for ovulation induction for patients with clomiphene citrate failure. Arch Gynecol Obstet. 2013; 288(2):445-8. DOI: 10.1007/s00404-013-2780-5. View

3.
Sabatini L, Lower A, Wilson C, Al-Shawaf T, Grudzinskas J . Does pretreatment with progestogen or oral contraceptive pills in low responders followed by the GnRHa flare protocol improve the outcome of IVF-ET?. J Assist Reprod Genet. 2000; 17(3):140-6. PMC: 3455662. DOI: 10.1023/a:1009462004650. View

4.
van Santbrink E, Hop W, Fauser B . Classification of normogonadotropic infertility: polycystic ovaries diagnosed by ultrasound versus endocrine characteristics of polycystic ovary syndrome. Fertil Steril. 1997; 67(3):452-8. DOI: 10.1016/s0015-0282(97)80068-4. View

5.
Yildiz B . Approach to the patient: contraception in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2015; 100(3):794-802. DOI: 10.1210/jc.2014-3196. View